Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast Cancer
April 23rd 2020Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.
Read More